Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.
Press release date / time: Tuesday, August 8, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Wednesday, August 9, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.
Three options for joining the conference call
1.Register for call back connection – Click here: Connect me
Service available 15 minutes before call start
2. Dial-in by phone
U.S.: +1 646 828 8193
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2490
Conference ID: 4878029
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
3. Access the audio webcast – Click here: Access Webcast
A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1596354&tp_key=0acb730754
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to
Insight solutions that enable customers to gain valuable molecular insights from samples containing
the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from
blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for
analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable
insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN
provides solutions to more than 500,000 customers around the world in Molecular Diagnostics
(human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily
forensics). As of March 31, 2023, QIAGEN employed more than 6,200 people in over 35 locations
worldwideFurther information can be found at http://www.qiagen.com.
source: QIAGEN N.V.
category: Financial
CONTACT: John Gilardi QIAGEN N.V. +49 2103 29 11711 ir@qiagen.com Phoebe Loh QIAGEN N.V. +4921032911457 ir@qiagen.com
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…
12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…